Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

The role of CMV in glioblastoma and implications for immunotherapeutic strategies.

Rahman M, Dastmalchi F, Karachi A, Mitchell D.

Oncoimmunology. 2018 Oct 16;8(1):e1514921. doi: 10.1080/2162402X.2018.1514921. eCollection 2019. Review.

2.

Recognition and killing of autologous, primary glioblastoma tumor cells by human cytomegalovirus pp65-specific cytotoxic T cells.

Nair SK, De Leon G, Boczkowski D, Schmittling R, Xie W, Staats J, Liu R, Johnson LA, Weinhold K, Archer GE, Sampson JH, Mitchell DA.

Clin Cancer Res. 2014 May 15;20(10):2684-94. doi: 10.1158/1078-0432.CCR-13-3268. Epub 2014 Mar 21.

3.

Ex vivo functional analysis, expansion and adoptive transfer of cytomegalovirus-specific T-cells in patients with glioblastoma multiforme.

Crough T, Beagley L, Smith C, Jones L, Walker DG, Khanna R.

Immunol Cell Biol. 2012 Oct;90(9):872-80. doi: 10.1038/icb.2012.19. Epub 2012 Apr 17.

PMID:
22508289
4.

Is CMV a target in pediatric glioblastoma? Expression of CMV proteins, pp65 and IE1-72 and CMV nucleic acids in a cohort of pediatric glioblastoma patients.

Wakefield A, Pignata A, Ghazi A, Ashoori A, Hegde M, Landi D, Gray T, Scheurer ME, Chintagumpala M, Adesina A, Gottschalk S, Hicks J, Powell SZ, Ahmed N.

J Neurooncol. 2015 Nov;125(2):307-15. doi: 10.1007/s11060-015-1905-z. Epub 2015 Sep 4.

5.

CMV-independent lysis of glioblastoma by ex vivo expanded/activated Vδ1+ γδ T cells.

Knight A, Arnouk H, Britt W, Gillespie GY, Cloud GA, Harkins L, Su Y, Lowdell MW, Lamb LS.

PLoS One. 2013 Aug 7;8(8):e68729. doi: 10.1371/journal.pone.0068729. eCollection 2013.

6.

Autologous T-cell therapy for cytomegalovirus as a consolidative treatment for recurrent glioblastoma.

Schuessler A, Smith C, Beagley L, Boyle GM, Rehan S, Matthews K, Jones L, Crough T, Dasari V, Klein K, Smalley A, Alexander H, Walker DG, Khanna R.

Cancer Res. 2014 Jul 1;74(13):3466-76. doi: 10.1158/0008-5472.CAN-14-0296. Epub 2014 May 4.

7.

Immunological targeting of cytomegalovirus for glioblastoma therapy.

Nair SK, Sampson JH, Mitchell DA.

Oncoimmunology. 2014 Jun 25;3:e29289. eCollection 2014.

8.

Generation of polyclonal CMV-specific T cells for the adoptive immunotherapy of glioblastoma.

Ghazi A, Ashoori A, Hanley PJ, Brawley VS, Shaffer DR, Kew Y, Powell SZ, Grossman R, Grada Z, Scheurer ME, Hegde M, Leen AM, Bollard CM, Rooney CM, Heslop HE, Gottschalk S, Ahmed N.

J Immunother. 2012 Feb-Mar;35(2):159-68. doi: 10.1097/CJI.0b013e318247642f.

9.

The detection of CMV pp65 and IE1 in glioblastoma multiforme.

Lucas KG, Bao L, Bruggeman R, Dunham K, Specht C.

J Neurooncol. 2011 Jun;103(2):231-8. doi: 10.1007/s11060-010-0383-6. Epub 2010 Sep 5.

PMID:
20820869
10.

Cytomegalovirus and glioblastoma; controversies and opportunities.

Lawler SE.

J Neurooncol. 2015 Jul;123(3):465-71. doi: 10.1007/s11060-015-1734-0. Epub 2015 Feb 15. Review.

PMID:
25682092
11.

Cytomegalovirus as a novel target for immunotherapy of glioblastoma multiforme.

Schuessler A, Walker DG, Khanna R.

Front Oncol. 2014 Oct 7;4:275. doi: 10.3389/fonc.2014.00275. eCollection 2014. Review.

12.

Dendritic cells cross-talk with tumour antigen-specific CD8+ T cells, Vγ9γδT cells and Vα24NKT cells in patients with glioblastoma multiforme and in healthy donors.

Eiraku Y, Terunuma H, Yagi M, Deng X, Nicol AJ, Nieda M.

Clin Exp Immunol. 2018 Oct;194(1):54-66. doi: 10.1111/cei.13185. Epub 2018 Sep 14.

13.

Novel mechanisms and approaches in immunotherapy for brain tumors.

Finocchiaro G, Pellegatta S.

Discov Med. 2015 Jul-Aug;20(108):7-15. Review.

14.

Cytomegalovirus and brain tumor: epidemiology, biology and therapeutic aspects.

Cobbs CS.

Curr Opin Oncol. 2013 Nov;25(6):682-8. doi: 10.1097/CCO.0000000000000005. Review.

PMID:
24097102
15.

Cytomegalovirus-targeted immunotherapy and glioblastoma: hype or hope?

Ferguson SD, Srinivasan VM, Ghali MG, Heimberger AB.

Immunotherapy. 2016;8(4):413-23. doi: 10.2217/imt.16.2. Review.

PMID:
26973123
16.

Discordant humoral and cellular immune responses to Cytomegalovirus (CMV) in glioblastoma patients whose tumors are positive for CMV.

Rahbar A, Peredo I, Solberg NW, Taher C, Dzabic M, Xu X, Skarman P, Fornara O, Tammik C, Yaiw K, Wilhelmi V, Assinger A, Stragliotto G, Söderberg-Naucler C.

Oncoimmunology. 2015 Feb 25;4(2):e982391. eCollection 2015 Feb.

17.

Tumor antigen-specific T cells for immune monitoring of dendritic cell-treated glioblastoma patients.

Müller I, Altherr D, Eyrich M, Flesch B, Friedmann KS, Ketter R, Oertel J, Schwarz EC, Technau A, Urbschat S, Eichler H.

Cytotherapy. 2016 Sep;18(9):1146-61. doi: 10.1016/j.jcyt.2016.05.014. Epub 2016 Jul 14. Erratum in: Cytotherapy. 2017 Jan;19(1):153.

PMID:
27424145
18.

Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival.

Poli A, Wang J, Domingues O, Planagumà J, Yan T, Rygh CB, Skaftnesmo KO, Thorsen F, McCormack E, Hentges F, Pedersen PH, Zimmer J, Enger PØ, Chekenya M.

Oncotarget. 2013 Sep;4(9):1527-46.

19.

Immunotherapy with dendritic cells loaded with glioblastoma stem cells: from preclinical to clinical studies.

Finocchiaro G, Pellegatta S.

Cancer Immunol Immunother. 2016 Jan;65(1):101-9. doi: 10.1007/s00262-015-1754-9. Epub 2015 Sep 16. Review.

PMID:
26377689
20.

Preclinical evaluation of ex vivo expanded/activated γδ T cells for immunotherapy of glioblastoma multiforme.

Bryant NL, Gillespie GY, Lopez RD, Markert JM, Cloud GA, Langford CP, Arnouk H, Su Y, Haines HL, Suarez-Cuervo C, Lamb LS Jr.

J Neurooncol. 2011 Jan;101(2):179-88. doi: 10.1007/s11060-010-0245-2. Epub 2010 Jun 10.

PMID:
20532954

Supplemental Content

Support Center